Study		Exclusion reasons	Remarks	Reference(s)
BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020	randomized controlled trial			Mitja O et al. Lancet preprint
HYDRA, 2020	randomized controlled trial		Initially found in Axfors et al. meta-analysis results published by Hernadez et al
CloroCOVID19, 2020	randomized controlled trial	inadequate or absent control group	This paper reports partial results from an unplanned interim analysis.Efficacy and safety criteria do not appear to have ever been assessed on the same number of patients (denominators are different for almost every criterion and are less than the number of patients randomized). Compared to the registration record, the patient eligibility criteria were changed.	Borba JAMA Netw Open 2020; 3:e208857 10.1001/jamanetworkopen.2020.8857 Mayla Borba for CloroCovid-19 Team medRxiv 2020.04.07.20056424
Raquel, 2019	randomized controlled trial	other reason		Raquel Benedita Terrabuio Hepatol Commun 2019; 3:116-128 10.1002/hep4.1275
ChiCTR2000029975, 0	single-arm	not relevant study design
Jacobson, 2016	randomized controlled trial	not relevant study design		Jacobson AIDS Res. Hum. Retroviruses 2016; 32:636-47 10.1089/AID.2015.0336
Sperber, 1995	randomized controlled trial	not relevant outcome		Sperber Clin Ther ; 17:622-36 10.1016/0149-2918(95)80039-5
Paton, 2012	randomized controlled trial	not relevant outcome		Paton JAMA 2012; 308:353-61 10.1001/jama.2012.6936
ChiCTR2000029826 (Cancelled by the investigator), 0	randomized controlled trial	cancelled by investigator
Duke university (Hydroxychloroquine), 2020	randomized controlled trial	cancelled by investigator
Million, 2020	single-arm	no control group		Million Travel Med Infect Dis 2020; :101738 10.1016/j.tmaid.2020.101738
Mohana, 2020	retrospective cohort (claims database)	no control group		Mohana A Int J Infect Dis 2020 Oct 16;S1201-9712(20)32235-9. 10.1016/j.ijid.2020.10.031
Thakar, 2021	randomized controlled trial	no clinically relevant endpoint		Thakar A Indian J Med Res 2021 Jan 21. 10.4103/ijmr.IJMR_3665_20
Barbosa, 2020	retrospective cohort	other	the only document variable for this study is a copy of a submission to NEJM. It is impossible to verify the veracity of this document. The paper was submitted apr 4th and since this date ther is no publication in NEJM or in other media (included preprint server).
Mallat, 2020	retrospective cohort	other	inapropriate statistical analysis. Time to events analyszed with means without taken into account the censure due to death or lost to follow-up	Jihad Mallat, Fadi Hamed, Maher Balkis, Mohamed A Mohamed, Mohamad Mooty, Asim Malik, Ahmad Nusair, Fernanda Bonilla medRxiv 2020.04.27.20082180 10.1101/2020.04.27.20082180
Mehra, 2020	retrospective cohort	other	the paper was retracted by 3 authors on June 4, 2020	Mehra MR Lancet 2020 May 22;S0140-6736(20)31180-6. 10.1016/S0140-6736(20)31180-6 Mehra MR Lancet 2020 Jun 13;395(10240):1820. 10.1016/S0140-6736(20)31324-6
Guerin, 2020	non randomized controlled trial	other	no binary endpoints	Guérin, Preprints 2020, 2020050486 (doi: 10.20944/preprints202005.0486.v1).
Kanran M, 2020	randomized controlled trial	other	randomization process unclear : Thepatients who did not give consent for treatment with HCQ or had a known allergy to HCQ orchloroquine or had another known contraindication to treatment with the study drug, includingretinopathy, G6PD deficiency and QT prolongation served as controls	sultan mehmood kamran medRxiv 10.1101/2020.07.30.20165365
Alberici, 2020	retrospective cohort	other	HCQ efficacy or safety evaluation wasn't a prespecified endpoint	Alberici F Kidney Int 2020 Jul;98(1):20-26. 10.1016/j.kint.2020.04.030
Thakar, 2021	randomized controlled trial	other	chloroquine nasal drops	Thakar A Indian J Med Res 2021 Jan & Feb;153(1 & 2):151-158. 10.4103/ijmr.IJMR_3665_20